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8ABSTRACT
Background and purpose
Short-term glucocorticoids (GCs) are frequently used in association with oral and maxillofacial 
surgery to prevent postoperative pain, edema, and nausea. However, the influence on tissue 
repair and the anti-inflammatory and immunosuppressive features of GCs may have an adverse 
impact on healing of the surgical site. The main aim of this study was to determine the 
occurrence of disturbance in surgical wound healing (DSWH) (Studies I–III) and pulp necrosis 
(PN) (Study IV) after surgical treatment of facial fractures and the influence of perioperative 
administration of GCs on these complications. 
Patients
This study comprised four populations of patients (Studies I–IV) treated for facial fractures 
at the Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital, 
Helsinki, Finland. For Study I, the medical records of 280 consecutive patients who had 
undergone open reduction of different types of facial fractures or reconstruction of orbital wall 
fracture between January 1, 2003 and December 31, 2004 were retrieved from the database of 
the Department of Oral and Maxillofacial Diseases. The populations of Studies II and III were 
recruited at the department between June 1, 2006 and December 31, 2010. Study II comprised 
dentate patients who had simple mandibular fractures and were scheduled to undergo surgery 
through an intraoral approach (n=41). In Study III, patients with a simple zygomatic complex 
(ZC) fracture who were to undergo surgery through an extra- and/or intraoral approach (n=64) 
were recruited. The fourth population (n=24) (Study IV) was extracted from the population of 
patients with mandibular fractures recruited for Study II. Included in the analysis were those 
who had a fracture line in the tooth-bearing area anterior to the third molar. 
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In the retrospective study (Study I), the outcome variable was DSWH, which was established 
when any kind of aberrant wound healing and/or sign of infection in the surgical site occurred. 
The primary predictor variable was the perioperative use of GC.
Patients recruited for Studies II and III were randomly assigned to one of two groups. 
Patients in the study group received dexamethasone (DXE) (Oradexon®), whereas patients in 
the control group received no GC. Patients were followed up one day, two days, one week, 
one month, three months, and six months postoperatively. The main outcome variables were 
DSWH (Studies II–III) and PN of teeth in the area of mandibular fracture (Study IV). The 
primary predictor variable was the perioperative use of DXE. 
Chi-square and Fisher’s exact tests were used to study statistical significance of associations 
between outcome and categorized predictor variables. Wilcoxon two-sample test was used to 
evaluate differences in means of continuous variables. 
Results
In patients operated on for ZC fractures (Study III), DSWH was significantly associated with 
perioperative use of DXE as well as with intraoral surgical approach. In patients operated 
on for different types of facial fractures (Study I), DSWH was associated significantly with 
intraoral surgical approach. In these patients, no significant association between DSWH and 
perioperative use of GCs was found; however, DSWH occurred more frequently in patients 
receiving GCs. In patients undergoing intraoral surgery for mandibular fractures (Study II), 
DSWH occurred more frequently in the DXE group. Also PN occurred more frequently in 
the DXE group (Study IV). 
In patients with different types of facial fractures (Study I), all six patients who had received 
perioperative GCs and who ended up with DSWH had received the maximal number of GC 
doses used in the study population, i.e., a total of three 10-mg doses given at 8-hour intervals. 
In patients with different types of facial fractures (Study I), mandibular fractures (Study 
II), and ZC fractures (Study III), the delay of DSWH was notably longer in the DXE groups. 
Particularly PN (Study IV) was observed much later in the DXE group. 
10
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Conclusions
Perioperative DXE cannot be recommended in association with surgery of ZC fractures. 
Moreover, GCs should be used with caution in association with surgery of other facial fractures 
as well, particularly when the intraoral approach is used. Patients who have teeth retained in 
the mandibular fracture line, in particular those who additionally receive perioperative GCs, 
should be referred to the general dentist for regular, long-term follow-up so that endodontic 
treatment can be initiated immediately when needed. 
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1. INTRODUCTION
Due to their anti-inflammatory effects, glucocorticoids (GCs) are widely used in association 
with surgery in order to decrease tissue reactions that cause discomfort postoperatively. GCs 
have been shown to successfully reduce swelling after various types of surgical procedures (Daull, 
Paterson et al. 2013, Tuncel, Turan et al. 2013). In association with oral and maxillofacial 
surgery in particular, GCs reduce both swelling (Dan, Thygesen et al. 2010) and pain (Dan, 
Thygesen et al. 2010, Markiewicz, Brady et al. 2008). GCs also reduce nausea caused by general 
anesthesia (Doksrod, Sagen et al. 2012, Bisgaard, Klarskov et al. 2003). 
When GCs are applied perioperatively for the above-mentioned reasons, the duration of 
medication is short-lived, but the doses are usually high. Potential complications of high-dose 
application of GCs are avascular necrosis (Hussain, Young 2007, Chan, Chan et al. 2006, 
Wong, Poon et al. 2005), psychosis (Natkunarajah, Goolamali et al. 2011, Ularntinon, Tzuang 
et al. 2010, Fleming, Flood 2005, Galen, Beck et al. 1997), gastrointestinal ulcer (Olsen, 
Christensen et al. 2010, O’Neil, Chwals et al. 1992), and even gastrointestinal perforation 
and bleeding (Fadul, Lemann et al. 1988). In addition, GCs impair the immune defense by 
various mechanisms (Schimmer, Parker 2006), and short-term, high-dose usage might have 
such adverse effects as infections and impairment of surgical site healing. 
In animals, delayed healing of the surgical wound has been shown to occur after short-
term use of GCs (Li, Wang et al. 2012, Durmus, Karaaslan et al. 2003, Wicke, Halliday et 
al. 2000). Human studies, on the other hand, reveal contradictory results. The use of GCs in 
association with thyroid surgery, laparoscopic cholecystectomy, laparotomy for endometrial 
cancer, or cardiac surgery has not caused any problems in surgical wound healing (Bolac, Wallace 
et al. 2013, Doksrod, Sagen et al. 2012, Dieleman, Nierich et al. 2012, Bisgaard, Klarskov 
et al. 2003, Polat, Nayci et al. 2002). Studies that have focused on surgical procedures in the 
oral cavity have also yielded contradictory results. In some studies, GCs caused no adverse 
effects on oral surgical wound healing (Bortoluzzi, Capella et al. 2013, Antunes, Avelar et al. 
2011, Dan, Thygesen et al. 2010, Markiewicz, Brady et al. 2008), whereas other authors have 
observed higher rates of fistulas, alveolar osteites, and other manifestations of infection (Dan, 
Thygesen et al. 2010, Senders, Di Mauro et al. 1999). 
There is a significant lack of investigations focusing on the benefits and drawbacks of GC 
use in association with surgical treatment of facial fractures. To date, we have found only one 
randomized study on this topic (Flood, McManners et al. 1999). The authors of that study 
12
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observed significant benefits of short-term, high-dose methylprednisolone on tissue recovery 
after surgery of traumatized orbits. No complications related to GC were reported; however, 
the patients were followed up for 72 hours only, a time-span that is far too short to identify 
GC-related problems. Considering the fact that GCs are widely used in association with 
craniofacial surgery (Assimes, Lessard 1999), an obvious need for investigations about the 
drawbacks of GC use in this context exists. 
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2. REVIEW OF THE LITERATURE
2.1 Facial fractures
Facial fractures are frequent in traumatized patients, and, vice versa, patients with facial injuries 
frequently have injuries in other parts of the body (Thorén, Snäll et al. 2010, Follmar, Debruijn 
et al. 2007). Assault is the main mechanism of facial fractures in Finland (Thorén, Snäll et 
al. 2010), parallel findings also arising from other Western countries (Allareddy, Allareddy et 
al. 2011, van den Bergh, van Es et al. 2011). Other common trauma mechanisms are traffic 
accidents (van Hout, Van Cann et al. 2012, Naveen Shankar, Naveen Shankar et al. 2011, 
Kontio, Suuronen et al. 2005, Gassner, Tuli et al. 2003), falls (Singh, Malkunje et al. 2012), 
bicycle accidents (Boffano, Roccia et al. 2013), and sports-related accidents (van Hout, Van 
Cann et al. 2012, Zix, Schaller et al. 2011). Men are involved more often than women, 
especially when it comes to assault-related injuries (van den Bergh, van Es et al. 2011, Thorén, 
Snäll et al. 2010). 
A nasal bone fracture is the single most common 
facial fracture, other common injuries being mandibular 
fractures and fractures of the zygomatico-orbital complex 
(Kyrgidis, Koloutsos et al. 2013, van Hout, Van Cann 
et al. 2012, Naveen Shankar, Naveen Shankar et al. 
2011, Thorén, Snäll et al. 2010). Facial fractures are also 
frequently multiple and severe (Figure 1) (Thorén, Snäll 
et al. 2010). 
Facial fractures that cause esthetic and/or functional 
disturbances need to be corrected surgically. The fracture 
site is exposed, after which the fractured fragments are 
adjusted to the correct position and fixed with plates 
and screws. The injury itself (Figure 2) and surgical 
intervention cause swelling and pain, indicating the use of 
anti-inflammatory drugs during and after surgery. On the 
other hand, delayed healing of the wound and infections 
Figure 1. Severe midfacial fracture 
as a result of an assault. The 
three-dimensional computer 
tomography reconstruction 
shows combination of Le Fort 
I–III type fractures. The upper 
fracture lines extend to the base 
of the skull. The right bony orbit 
is widely fragmented.
14
revIew of the lIterAture
at the surgical site remain the main complications of facial 
fracture surgery (Ellis 2013, Salentijn, van den Bergh 
et al. 2013). Therefore, anti-inflammatory drugs, which 
may impair wound healing and cause surgical infections, 
should be used with caution. 
2.2 Healing of soft tissues
Repair of soft tissues can be divided into three main 
phases: inflammation, proliferation, and maturation. These 
complex processes occur partly contemporaneously. The 
inflammatory phase includes hemostasis and inflammation. 
Proliferation includes remodeling and granulation. 
Maturation, which may last from months to years, includes re-epithelization and tissue formation. 
Surgical wounds are mainly clean wounds without tissue defects. Therefore, the sides of 
the wounds can be settled against each other, leading to healing by primary union. In more 
complex wounds, the healing process is slower due to tissue loss, and the healing process 
requires more connective tissue and scar formation; this form of healing is called healing by 
secondary union. This also takes place if healing by primary union fails. The complex process of 
healing is regulated by proteases, cytokines, chemokines, peptides, and genetic characteristics 
(Schreml, Szeimies et al. 2010).
Clinically, the most important cause of delay in wound healing is infection. Other important 
factors that influence tissue repair are nutrition, perfusion, mechanical variables (such as degree 
of local pressure), possible foreign bodies in the wound, and several diseases and medications 
(Kumar, Abbas et al. 2012)
2.3 Basic mechanisms of fracture healing
Bone healing follows the mechanisms of soft tissue repair and is regulated by similar complex 
mechanisms (Arvidson, Abdallah et al. 2011, Phillips 2005, Einhorn 1998). Fracture healing 
is divided into two phases; primary and secondary. In primary healing, osteoclasts migrate 
across the fracture site, resulting in high bone stability (Phillips 2005). In secondary healing, 
a mass of non-calcified soft tissue callus is first created, followed by cartilage synthesis (Kumar, 
Abbas et al. 2012, Phillips 2005). Ossification of the callus optimally results in the original 
size, shape, and integrity of the bone. 
Figure 2. Recent fracture of the 
left zygomatic bone causing 
significant swelling of the lower 
lid and cheek
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From a clinical point of view, displaced and comminuted fractures as well as inadequate 
fracture immobilization are significant factors that increase the risk for incomplete healing 
(Kumar, Abbas et al. 2012).
2.4 Glucocorticoids
GCs (i.e., in humans, cortisol and its biologically active synthetic derivatives) are a group of 
steroid hormones that affect the metabolism of carbohydrates, fats, and proteins, in addition 
to many other effects. 
Cortisol is synthesized and released from the adrenal cortex following activation of the 
hypothalamic-pituitary-adrenal axis, which is induced by stress. The hypothalamic corticotropin-
releasing hormone (CRH) regulates secretion of adrenocorticotropic hormone (ACTH) in 
the pituitary. ACTH stimulates the adrenal cortex to secrete GCs, mineralocorticoids, and 
dehydroepiandrosterone (DHEA). GCs are bound to plasma proteins and transported to tissues 
to interact with specific receptor proteins. GC receptors are found in nearly every cell of the 
human. Recent studies have indicated that GCs act through several receptor subtypes instead of 
a single GC receptor (Oakley, Cidlowski 2011, Bray, Cotton 2003). Their contribution to the 
sensitivity and specificity of the GC response is currently of interest (Oakley, Cidlowski 2011). 
2.4.1 Synthetic glucocorticoids in medicine
The immunosuppressive and anti-inflammatory actions of GCs are well known. Their effects 
are mediated by multiple mechanisms, and the network of the cascades is extensive. Although 
the immunosuppressive effects of GCs in general are widely known, the precise mechanisms 
remain unclear (Oakley, Cidlowski 2011, Didonato, Saatcioglu et al. 1996, Marx 1995). 
Suppression of inflammation is caused by a decreased release of vasoactive and chemoattractive 
factors, diminished secretion of proteolytic and lipolytic enzymes, decreased fibrosis, a lower 
number of circulating lymphocytes, and reduced extravasation of leucocytes to the site of injury 
(Schimmer, Parker 2006). Due to these effects, GCs are used to treat several autoimmune 
diseases, acute and chronic inflammatory diseases, organ transplant rejection, and malignancies 
of the lymphoid system (Rhen, Cidlowski 2005). GCs can also be used to substitute deficiencies 
in secretion of human cortisol. 
GCs have several side-effects that need to be considered. They may depress the function 
of the adrenal cortex, leading to a decreased secretion of cortisol. Other significant side-effects 
are immunodeficiency, osteoporosis, changes in glucose and fat metabolism, and atrophy of 
skin and muscles. 
16
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Various synthetic GCs are available for several medical applications. Synthetic GCs differ 
from each other with regard to pharmacokinetics and pharmacodynamics (Table 1). Therefore, 
GCs can be chosen based on the desired effects. 
2.4.2 Short-term glucocorticoids
The short-term use of GCs differs from long-term use, the benefits and side-effects being 
somewhat different. In short-term use, the dosages are usually higher and a wider potency is 
preferred than in long-term use. 
2.4.2.1 Benefits
To diminish postoperative nausea and vomiting, anesthesiologists favor dexamethasone (DXE) 
(Diakos, Gallos et al. 2011, Karanicolas, Smith et al. 2008, Bolton, Myles et al. 2006, Bisgaard, 
Klarskov et al. 2003). DXE is also effective in reducing pain in general (De Oliveira, Almeida 
et al. 2011, Diakos, Gallos et al. 2011, Steward, Grisel et al. 2011, Afman, Welge et al. 
2006, Bisgaard, Klarskov et al. 2003) and especially migraine headache (Colman, Friedman 
et al. 2008). In cardiac surgery patients, recovery improved significantly when DXE was used 
(Murphy, Sherwani et al. 2011).
Table 1. Relative potencies and equivalent doses of glucocorticoids.
Glucocorticoid Anti-
inflammatory 
potency
Relative 
mineralo-
corticoid 
activity
Relative 
glucocorticoid 
activity
Biological  
half-life*
Equivalent 
dose in oral 
or intravenous 
administration 
(mg)
Cortisol  
(Hydrocortisone) 1 1 1 short 20
Cortisone 0.8 0.8 0.8 short 25
Prednisone 4 0.8 4 intermediate 5
Prednisolone 4 0.8 4 intermediate 5
Methyl-
prednisolone 5 0.5 5 intermediate 4
Triamcinolone 5 0 5 intermediate 4
Betamethasone 25 0 20–30 long 0.75
Dexamethasone 25 0 20–30 long 0.75
*short: 8–12 hours, intermediate: 12–36 hours, long: 36–54 hours
Modified from Goodman & Gilman´s The Pharmacologian Basis of Therapeutics 11th edition, 2005. 
Table 59-2 p. 1594.
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GCs have been proven to reduce edema after various types of interventions such as 
ophthalmologic interventions (Daull, Paterson et al. 2013, Grover, Li et al. 2008), neurosurgery 
(Kotsarini, Griffiths et al. 2010), rhinological procedures (Tuncel, Turan et al. 2013, Hatef, 
Ellsworth et al. 2011), and surgery of fractured orbits (Flood, McManners et al. 1999). 
GCs have been studied as adjunct therapy in patients with serious infections, but a consistent 
view of their benefits has yet to emerge (De Pascale, Bello et al. 2011, Moran, Graham et 
al. 2010, Agarwal, Nath et al. 2007). GCs appear to be beneficial when low doses are used, 
whereas adverse effects seem to increase when doses are increased (Minneci, Deans et al. 2004).
2.4.2.2 Drawbacks
GCs occasionally have serious side-effects, particularly when high doses are used. The risk 
for adrenal suppression in association with short-term use continues for several months after 
the medication ceases (Henzen, Suter et al. 2000). Short-term GCs increase the risk for 
avascular osteonecrosis (Hussain, Young 2007, Chan, Chan et al. 2006, Wong, Poon et al. 
2005). Even though the cases are rare, the literature reports GC-induced psychosis, especially 
in connection with high doses (Natkunarajah, Goolamali et al. 2011, Ularntinon, Tzuang 
et al. 2010, Fleming, Flood 2005, Galen, Beck et al. 1997). GCs have also been shown to 
increase the incidence of peptic ulcers and gastrointestinal bleeding (O’Neil, Chwals et al. 
1992), and high-dose GC use is associated with a greater increase in mortality following 
peptic ulcer bleeding (Olsen, Christensen et al. 2010). In addition, short-term GCs have 
various adverse effects on tissue healing. 
2.4.3 Effects of short-term glucocorticoids on tissue healing
The altered cellular function caused by GCs is transmitted through induction of gene 
transcription (Schimmer, Parker 2006). The GC receptor interacts with proteins, which control 
proinflammatory gene expression (Stocklin, Wissler et al. 1996), inducing diminished healing 
(Sanchis, Alba et al. 2012). GCs can also induce apoptosis (Schlossmacher, Platt et al. 2013, 
Zhu, Zhao et al. 2013, Yang, Lou et al. 2011). In addition to direct cellular influences, there 
are several other GC-related mechanisms that should be taken into consideration in surgical 
wound healing.
18
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2.4.3.1 Altered functions in periphery
GCs alter the functions and concentrations of cells critical in inflammatory response and tissue 
repair. They affect the concentration of blood cells by decreasing the numbers of circulating 
lymphocytes, eosinophils, basophils, and monocytes and increasing the numbers of circulating 
polymorphonuclear granulocytes and stab cells (Derendorf, Hochhaus et al. 1993). GCs also 
increase blood glucose levels (Doksrod, Sagen et al. 2012, Nazar, Lacassie et al. 2009, Derendorf, 
Hochhaus et al. 1993) and inhibit the proliferation of fibroblasts (Ramalingam, Hirai et al. 
1997). Moreover, GCs decrease collagen synthesis and levels of growth factors in wounds 
(Wicke, Halliday et al. 2000). 
GCs play a role in vascular tone and vascularization. GCs control vascular tone by suppressing 
vasodilatation in endothelial cells (Jun, Chen et al. 1999, Zingarelli, Caputi et al. 1994) and 
have an indirect effect on vascular tone by increasing vascular sensitivity to vasoconstrictors in 
vascular smooth muscle cells (Xiao, Huang et al. 2003). In addition, GCs inhibit the growth 
of blood vessels (Hasan, Tan et al. 2000, Folkman, Langer et al. 1983). Especially DXE has 
been shown to inhibit angiogenesis (Hori, Hu et al. 1996). Although the precise mechanisms 
remain unresolved, it has been established that GCs interact directly with GC receptors on 
vascular endothelial cells (Logie, Ali et al. 2010). Genetic variations of GC receptors also 
have a significant consequence in vasoconstriction (Kumsta, Entringer et al. 2008). Table 2 
summarizes the influence of GCs on different cell types in the periphery.
The above-mentioned various effects of GCs on cells and molecules show that even short-
term GCs have a significant potential to impair surgical site healing.
Table 2.  Main effects of glucocorticoids on different cell types in inflammatory and immune responses 
according to literature.
Cell type Influence of glucocorticoids Mechanisms
Polymorphonuclear 
leucocytes Increase of circulating cells
- increased release from  
the marrow
- diminished rate of removal from 
circulation
Lymphocytes, eosinophils, 
basophils, and monocytes Decrease of circulating cells
- redistribution of cells away from 
the periphery
Fibroblasts Decrease of acting cells - inhibition of proliferation- reduction of cell viability
Endothelial cells Decrease of acting cells,vasoconstriction
- suppression of vasodilatation
- effects on vasoconstrictors
- inhibition of proliferation
Vascular smooth  
muscle cells Vasoconstriction
- increase of vascular sensitivity  
to vasoconstrictors
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2.4.3.2 Short-term glucocorticoids and surgical site recovery
Several animal studies have shown that use of short-term GCs in association with surgery 
predisposes to imperfect wound healing (Li, Wang et al. 2012, Durmus, Karaaslan et al. 
2003, Wicke, Halliday et al. 2000). Durmus et al. (2003) showed that a single dose of DXE 
1 mg/kg administered intraperitoneally in rats had a deleterious effect on wound healing 
(Durmus, Karaaslan et al. 2003). Also collagenization, epithelization, and fibroblast contents 
were significantly lower in rats receiving DXE than in those receiving physiological saline. 
Human studies, on the other hand, have yielded contradictory results about the adverse effects 
of GCs on surgical wound healing. 
In a study of thyroid surgery patients (Doksrod, Sagen et al. 2012), DXE showed no 
association with postoperative disturbance in wound healing. Another study found no evidence 
of an increased risk of surgical site infections after gynecological surgery when a single dose of 
DXE (4–12 mg) had been used (Bolac, Wallace et al. 2013, Eberhart, Holdorf et al. 2011). Also 
after uvulopalatopharyngoplasty, healing of the surgical wound was uneventful despite the use 
of GC (Williams, Strome et al. 1999). By contrast, a study focusing on non-emergency trauma 
patients revealed an increased risk of infections after surgery in patients who received DXE 
perioperatively (Percival, Riddell et al. 2010). The authors stated that DXE increases the risk 
of postoperative infection, particularly during the first postoperative month. A recent study of 
cardiac pediatric patients showed an association between duration of short-term corticosteroid 
exposure and postoperative infections (Mastropietro, Barrett et al. 2013). Several reasons exist 
for the discrepancies in results:  among others, the types, dosages, and durations of GCs as 
well as the types of surgical procedures vary significantly between the studies. 
2.5 Glucocorticoids in oral and maxillofacial surgery
The interest in the use of GCs in association with oral and maxillofacial surgery was awakened 
in the 1950s (Ross, White 1958, Stewart 1956). Since then, the usefulness of GCs has been 
investigated particularly in association with third molar surgery, and several studies have 
demonstrated benefits of GCs on recovery (Dan, Thygesen et al. 2010, Markiewicz, Brady 
et al. 2008). Local injection has shown benefits similar to those of systemic administration 
(Warraich, Faisal et al. 2013, Antunes, Avelar et al. 2011). According to a questionnaire filled 
out by oral and maxillofacial surgeons, perioperative GCs are favored especially because of 
their ability to reduce postoperative edema (Assimes, Lessard 1999), an effect that has been 
shown in several studies (Dan, Thygesen et al. 2010, Markiewicz, Brady et al. 2008, Flood, 
McManners et al. 1999). GCs also reduce pain after surgical procedures in the oral cavity in 
general (Dan, Thygesen et al. 2010) and have beneficial effects on neurosensory recovery after 
orthognathic surgery in particular (Al-Bishri, Rosenquist et al. 2004, Seo, Tanaka et al. 2004).
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The association between GC and disturbance in surgical site healing after oral surgery 
was discussed already in the late 1960s by Hooley et al. (1969). The investigators clarified the 
benefits and drawbacks of betamethasone in third molar surgery. Patients were randomized to 
receive either placebo or a total dose of 14.4 mg of betamethasone, which was administered over 
three days, beginning one day before surgery. A double-blind method was used. Forty-seven 
patients were included in the study, and a total of 94 third molars were extracted. Follow-up 
revealed alveolar osteitis in two patients, both of whom had received betamethasone. Since 
this study by Hooley et al., numerous randomized studies on the benefits of perioperative GC 
application in association with third molar surgery have been published, but very few report 
any surgical site complications. However, patients included in third molar studies have usually 
been followed up for only about one week (Bortoluzzi, Capella et al. 2013, Mehra, Reebye 
et al. 2013, Antunes, Avelar et al. 2011, Dan, Thygesen et al. 2010, Markiewicz, Brady et 
al. 2008). Since surgical site complications may occur several weeks after surgery (Monaco, 
Tavernese et al. 2009), a follow-up of one week is not sufficient. 
Some studies report that no complications occur in cleft palate surgery despite the use of 
GC (Bateman, Conejero et al. 2006, Senders, Emery et al. 1996). Another study has shown, 
however, a higher rate of postoperative palatal fistulas in patients receiving DXE (9%) than 
in those receiving placebo (4%) (Senders, Di Mauro et al. 1999). Although this finding was 
not statistically significant, it is notable.
A prospective randomized study of 33 patients who had undergone orthognathic surgery 
observed no complications related to perioperative GC administration (Weber, Griffin 1994). 
Another study focusing mainly on the benefits of GCs reported no complications in 39 patients 
undergoing orthognathic surgery, however, the follow-up was only 72 hours (Schaberg, Stuller 
et al. 1984). A third study that focused on 36 pediatric patients undergoing orthognathic 
surgery showed no surgical wound complications related to GC (Munro, Boyd et al. 1986), 
but two patients who had received GCs were reported to have postoperative bleeding. 
Clinical trials focusing on the use of GCs in facial trauma patients are scarce. Flood et 
al. published in 1999 a prospective, double-blind, randomized trial of 20 patients operated 
on for orbital blow-out fractures (Flood, McManners et al. 1999). The authors observed 
significant benefits of perioperatively applied GC. Those 11 patients who received 250 mg 
of methyprednisolone given four times at 6-hour intervals (i.e., a total dose of 1000 mg of 
methylprednisolone, which is equivalent to 190 mg of DXE) had a significantly increased 
interpalpebral width compared with those 9 patients who received placebo. Despite the high 
dosage, no complications appeared; however, the follow-up of patients was only 72 hours. 
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3. AIMS OF THE STUDY
The occurrence of disturbance in surgical wound healing (DSWH) and pulp necrosis (PN) 
after surgical treatment of facial fractures and the influence of perioperative glucocorticoid 
(GC) administration on these complications were evaluated.
Specific aims were as follows:
1. To clarify the types of GC regimens used in association with operative treatment of 
different facial fractures and the influence of GC on the occurrence of DSWH (Study I).
2. To determine the occurrence of DSWH after operative treatment of mandibular fracture 
and the influence of dexamethasone (DXE) (Study II). 
3. To determine the occurrence of DSWH after operative treatment of zygomatic complex 
(ZC) fracture and the influence of DXE (Study III). 
4. To evaluate the occurrence of PN of teeth in the fracture area after operative treatment 
of mandibular fracture and the influence of DXE (Study IV). 
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4. PATIENTS AND METHODS
4.1 Study populations
This study comprised four populations of patients (Studies I–IV) treated for facial fractures 
at the Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital, 
Helsinki, Finland. 
For the first study (I), the medical records of 280 consecutive patients who had undergone 
open reduction of different types of facial fractures (with or without osteosynthesis) or 
reconstruction of orbital wall fracture between January 1, 2003 and December 31, 2004 were 
retrieved from the database of the Department of Oral and Maxillofacial Diseases. 
The populations of Studies II–IV were recruited at the department between June 1, 2006 
and December 31, 2010. Patients included were at least 18 years old. Patients with infected 
fractures were excluded, as were patients with a history of liver dysfunction, kidney dysfunction, 
peptic ulcer, psychosis due to GC use, pregnancy, breastfeeding, or allergy to any constituent 
of the DXE preparation. 
Recruited patients for Study II (n=41) comprised dentate patients who had one or 2 simple, 
non-comminuted, and non-complicated mandibular fractures and who were to undergo open 
reduction and osteosynthesis through an intraoral approach with the aid of 2.0 mm titanium 
miniplates according to the technique described by Champy and Lodde (1976) (Figures 3–4). 
The fracture types included were classified as follows: one single fracture in the angle, one 
single fracture in the body, one single fracture in the symphysis/parasymphysis area, or a 
double mandibular fracture (i.e., angle + body, angle + symphyseal/parasymphyseal fracture). 
Recruited patients for Study III (n=64) comprised patients who had sustained a simple, 
non-comminuted ZC fracture (i.e. tripoid fracture) and were to undergo open reduction 
and fixation with the aid of one or more titanium miniplates through an extraoral and/or 
intraoral approach. Typical surgical access to the fronto-zygomatic suture through an upper 
blepharoplasty incision is shown in Figure 5 (page 26). Patients with any other facial fracture 
requiring surgery were excluded. 
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The fourth patient population (Study IV, n=24) was extracted from those patients with 
mandibular fractures who had been recruited for Study II. Patients with at least one fracture 
line in the tooth-bearing area anterior to the third molar were included. Excluded from the 
final analysis were patients with teeth in the fractured area that either showed signs of chronic 
periodontal or periapical pathologies on pre-operative radiographs, had undergone endodontic 
treatment before the injury, or were fractured in association with the injury. 
4.2 Outcome variables
The main outcome variables were DSWH (Studies I–III) and PN of teeth in the area of 
mandibular fracture (Study IV). DSWH was established when any kind of aberrant wound 
healing and/or sign of infection in the surgical site occurred. PN was confirmed in association 
with the initiation of endodontic treatment. 
Figure 3. Left mandibular angle fracture treated with one miniplate according to the technique described 
by Champy and Lodde (1976). A: Preoperative extraoral swelling at the fracture site. B: Preoperative 
radiological view of the angle fracture. C: Extraoral swelling on the second postoperative day. 
D: Postoperative radiological view after the repositioning and osteosynthesis of the fracture.
A b
dc
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4.3 Predictor variables
The primary predictor variable was the perioperative use of GC. Other predictor variables included 
in the analyses were gender and age (Studies I–IV), smoking habit (i.e., smoker or non-smoker) 
(Studies II and IV), site of fracture (Studies II and IV), type of fracture (Study I), treatment 
delay (i.e., time delay between accident and operative treatment) (Studies I–III), qualification 
of the surgeon (i.e., consultant or registrar) (Study I), surgical approach to the fracture line (i.e., 
intra- or extraoral), (Studies I and III), and duration of surgery (Studies II and III). 
In Study I, the predictor variable “fracture type” was determined for each patient from 
1 of the following 5 groups: 1) exclusively mandibular fracture (one or more), 2) exclusively 
zygomatico-orbital fracture (i.e., tripoid zygomatic fracture or isolated zygomatic arch fracture), 
3) exclusively orbital blow-out fracture (i.e., isolated orbital floor or medial wall fracture), 4) 
severe midfacial fracture (i.e., Le Fort I to III, naso-orbito-ethmoidal or multiple midfacial 
fracture), and 5) combined mandibular-midfacial or panfacial fracture. 
Figure 4. Fracture of the right parasymphysis area treated with two miniplates according to the 
technique described by Champy and Lodde (1976). A. Intraoral fractures site showing displacement. 
B. Preoperative radiological view of the mandibula. C. Postoperative radiological view. D. A periapical 
radiograph showing external resorption of d 41 three months after surgery.
A b
dc
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Figure 5. Surgical treatment of a right-sided zygomatic fracture through an upper blepharoplasty 
incision. A. Preoperative radiological view. B. Upper blepharoplasty incision. C. Fracture line at the 
frontozygomatic suture. D. Fracture stabilized with one (KLS Martin 1.5 mm) miniplate. E. Immediate 
postoperative view.
A
bc
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4.4 Dexamethasone regimens (Studies II and III)
For each facial fracture type, patients were randomly assigned to one of two groups. The 
patients in the study group received DXE (Oradexon®), whereas the patients in the control 
group received no GC. 
The patients in the study group received either a single dose of 10 mg of DXE intravenously 
during anesthesia induction (Study III) or an additional 10 mg intramuscularly every 8 hours 
over 16 hours, to a total dose of 30 mg of DXE (Studies II, III). All patients received antibiotics 
until the seventh to tenth postoperative day, starting with three 1.5-g doses of cefuroxime 
intravenously at the ward during the first 24 hours postoperatively, followed by three daily doses 
of 500 mg of cephalexin orally. Patients with allergies received four daily doses of clindamycin 
via corresponding routes. 
4.5 Clinical and radiological follow-up regimens 
(Studies II–IV)
Patients in Studies II–IV were followed-up clinically one day, two days, one week, one month, 
three months, and six months postoperatively. Patients received a longer follow-up for surgical 
reasons when needed. However, a postoperative follow-up period of 30 days (Studies II and 
III) or 3 months (Study IV) was required for a patient to be included in the final analysis. 
In patients with mandibular fracture (Studies II and IV), radiological investigation with 
panoramic imaging was done immediately and at one month, three months, and six months 
postoperatively. 
4.6 Evaluation of mandibular teeth in the fractured 
area (Study IV)
At each follow-up appointment, patients in Study IV were asked about dental symptoms. A 
routine clinical investigation of the teeth in the area of the mandibular fracture was performed, 
including an investigation with an electrical pulp tester. In addition to the routine investigations 
with panoramic imaging, teeth in the fractured areas were followed up with periapical x-rays 
(Figure 4D). Whenever there was a suspicion of a need for endodontic treatment, the patient 
was referred to an endodontist for further evaluation and therapy as required. 
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4.7 Statistics
Chi-square (Studies I–III) and Fisher’s exact (Study III) tests were used to evaluate significance 
of associations between outcome (DSWH in Studies I–III and PN in Study IV) and categorized 
predictor variables. Wilcoxon two-sample test was used to evaluate differences in means of 
continuous variables, including age, delay in treatment (days) (Study II), duration of operation 
(minutes) according to the occurrence of DSWH (Study II), delay in DSWH (days) (Studies 
I–III), and delay in PN (days) (Study IV). 
4.8 Ethical considerations
The protocol of Study I was approved by the Internal Review Board of the Division of 
Musculoskeletal Surgery, Helsinki University Central Hospital, Finland. The protocols of 
Studies II–IV were approved by the Research Ethics Board of the Department of Surgery and 
the Internal Review Board of the Division of Musculoskeletal Surgery, Helsinki University 
Central Hospital, Finland. All patients recruited for Studies II–IV signed a written consent. 
In addition, a signed written consent to publish facial photographs was obtained from those 
patients whose facial images are presented here. 
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Table 3. Descriptive statistics of 280 patients 
with different types of facial fractures (Study I).
Age Years
Range 11.2–72.6
Mean 35.9
Gender No. of 
patients
Female 57
Male 223
Glucocorticoid
yes 100
no 180
Fracture type
Exclusively mandibular  
(one or more)
122
Zygomatico-orbital 102
Exclusively orbital blow-out 20
Severe midfacial 26
Combined mandibular-midfacial 
or panfacial
10
Surgical approach
Exclusively extraoral 129
Intraoral or combined  
extra-intraoral
151
5. RESULTS
5.1 Glucocorticoid regimens used in association 
with operative treatment of different types of facial 
fractures and influence of glucocorticoids on the 
occurrence of disturbance in surgical wound healing 
(Study I)
Descriptive statistics of the 280 patients are 
shown in Table 3. GCs had been administered 
to 100 patients (35.7%). All patients had 
received antibiotic treatment, which was 
initiated on admission and continued for 7 
to 10 days postoperatively. 
As shown in Table 4, GC regimens varied 
significantly. The most frequently used GC was 
DXE (accounting for 82% of those receiving 
GCs), followed by methylprednisone (14%) 
and hydrocortisone (4%). The total number 
of doses varied from 1 to 3, and the total 
doses, as equivalent to DXE, varied from 3.8 
to 30 mg. The total length of medication varied 
from 1 to 24 hours. The single dose or first 
dose was administered intravenously during 
the operation to all patients. Postoperative 
doses were given either intravenously or 
intramuscularly. The most common regimen 
was DXE 10 mg every 8 hours over 16 hours 
(total dose 30 mg). 
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DSWH was observed in 11 patients (3.9%) on average 47 (range 7–161) days after surgery. 
DSWH occurred more often in patients who received GCs (6.0%) than in those who did not 
(2.8%), but the difference was not statistically significant. The occurrence of DSWH in patients 
who received DXE was dose-dependent: all patients with DSWH had received 30 mg of DXE 
over 16 hours, i.e., the overall largest DXE dose that had been used (Table 4). DSWH was 
established on average 52 days after surgery in patients receiving DXE, the corresponding delay 
in patients not receiving DXE being 42 days (p=ns). No significant correlation existed between 
DSWH and age, gender, treatment delay, fracture type, or qualification of the surgeon. The 
only significant predictor of DSWH was intraoral surgical approach (p < 0.001)
5.2 Occurrence of disturbance in surgical wound 
healing after operative treatment of mandibular 
fracture and influence of dexamethasone (Study II) 
A total of 49 patients fulfilled the inclusion criteria for Study II. Of these, 4 refused to 
participate. Of the remaining 45 patients, 4 were excluded: one because he attended no 
Table 4. Glucocorticoid regimens and occurrence of DSWH in 100 patients receiving perioperative 
glucocorticoids (Study I).
Dose Frequency Total 
dose 
(mg)
Total dose 
equivalent to 
dexamethasone 
(mg)
No. of 
patients
No. of 
patients 
with DSWH
Dexamethasone 5 mg Single dose 5 5 1 0
Dexamethasone 10 mg Single dose 10 10 20 0
Dexamethasone 5 mg Every 8 h 15 15 1 0
Dexamethasone 10 mg Every 8 h 20 20 3 0
Dexamethasone 10 mg Every 12 h 20 20 2 0
Dexamethasone 10 mg Every 8 h 30 30 53 6
Dexamethasone 10 mg Every 12 h 30 30 2 0
Hydrocortisone 100 mg Single dose 100 3.8 2 0
Hydrocortisone 250 mg Single dose 250 9.4 2 0
Methylprednisone 20 mg Single dose 20 3.8 1 0
Methylprednisone 40 mg Single dose 40 7.6 8 0
Methylprednisone 40 mg Every 8 h 80 15.2 3 0
Methylprednisone 40 mg Every 12 h 80 15.2 1 0
Methylprednisone 40 mg Every 8 h 120 22.8 1 0
DSWH: Disturbance in surgical wound healing
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follow-up appointments, one because he required an additional operation as the reduction 
of the fracture was unsatisfactory, and 2 because they failed to complete all doses. Forty-one 
patients were therefore followed up for at least one month. Descriptive statistics of the 41 
patients are shown in Table 5.
Table 6 shows the association between DSWH and predictors. DSWH was observed in 
13 patients (31.7%) on average 31 (range 2–93) days after surgery. A typical impairment 
of wound healing requiring plate removal is 
shown in Figure 6. DSWH occurred more 
often in patients who received GCs (35.0%) 
than in those who did not (28.6%), but the 
difference was not significant. In the DXE 
group, DSWH was established on average 
42 days after surgery, the corresponding 
delay in patients not receiving DXE being 
34 days (p=ns). No significant correlation 
existed between DSWH and gender, smoking 
habit, time span from accident to surgery, 
fracture site, or duration of surgery. The only 
significant predictor of DSWH was age over 
25 years (p=0.016).
Table 5. Descriptive statistics of 41 patients 
with mandibular fractures (Study II).
Age Years
range 18.1–50.9
mean 28.1
Gender No. of  
patients
% of  
41 patients
female 1 2.4
male 40 97.6
Dexamethasone
yes 20 48.8
no 21 52.2
Smoker
yes 27 65.9
no 14 34.1
Fracture localization
angle 15 36.6
body 2 4.9
symphysis/
parasymphysis
12 29.3
angle + body 2 2.9
angle + symphysis/
parasymphysis
10 24.4
Treatment delay Days
range 0–5
mean 2.1
Follow-up Days
range 30–680
mean 277
Duration of surgery Minutes
range 23–129
mean 53.9
Figure 6. Disturbance in surgical wound healing 
at four months after surgery of a mandibular 
parasymphysis fracture just before plate removal. 
Screws and plate (Synthes 2.0) are uncovered and 
needed to be removed to obtain adequate wound 
healing. The patient did not receive perioperative 
glucocorticoids.
32
results
Table 6. Association between DSWH and 
predictor variables in 41 patients with mandibular 
fractures (Study II).
DSWH 
present
% of n
Age group
18–25 years 4 20
> 25 years 9 43
p=0.016
Gender
female (n = 1) 1 100
male (n = 40) 12 30.0
p=ns
Dexamethasone
yes (n = 20) 7 35.0
no (n = 21) 6 28.6
p=ns
Smoker
yes (n = 27) 7 25.9
no (n = 14) 6 42.9
p=ns
Localization of DSWH
angle (n = 27) 9 33.3
body (n = 4) 1 25.0
symphysis/ 
parasymphysis (n = 22)
p=ns
3 13.6
Treatment delay 
(days)
< 2 (n=18) 4 22.2
≥ 2 <  3 (n=15) 6 40.0
≥ 3 ≤  5 (n=8) 3 37.5
p=ns
DSWH present (days postoperatively)
range 2–93
mean 38.4
median 33
DSWH: Disturbance in surgical wound healing
Table 7. Descriptive statistics of 64 patients with 
zygomatic complex fractures (Study III).
Age Years
range 22.2–83.8
mean 42.6
Gender No. of 
patients
% of n
female 18 28.1
male 46 71.9
Dexamethasone
yes 33 51.6
no 31 48.4
Treatment delay Days
range 1–18
mean 5
Follow-up Days
range 28–1022
mean 232
Duration of surgery Minutes
range 16–140
mean 48
5.3 Occurrence of disturbance in surgical wound 
healing after operative treatment of zygomatic 
complex fracture and influence of dexamethasone 
(Study III)
Seventy-three patients fulfilled the inclusion criteria for Study III. Of these, 8 patients were 
excluded because they were lost to follow-up before the 30th postoperative day and one because 
the patient required further surgery due to an unsatisfactory fracture reduction. Thus, a total 
of 64 patients were followed up for at least 
one month. Descriptive statistics of the 64 
patients are shown in Table 7. 
Associations between DSWH and 
predictors are presented in Table 8. DSWH 
occurred in 9 patients (14.1%) on average 
28 (range 7–92) days postoperatively. The 
clinical view of one of these patients is shown 
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Figure 7. Clinical view of a patient with slight 
swelling, redness, and pain of the right cheek 
one month after repositioning and osteosynthesis 
of a zygomatic fracture. The patient received a 
total dose of 30 mg of dexamethasone related 
to surgery.
Table 8. Association between DSWH and 
predictor variables in 64 patients with zygomatic 
complex fractures (Study III).
DSWH 
present
% of n
Gender
male (n=46) 5 10.9
female (n=18) 4 22.2
p=ns
Dexamethasone
yes (n=33) 8 24.2
no (n=31) 1 3.2
p=0.016
Total dose
Dexamethasone 30 mg 
(n=22)
5 22.7
Dexamethasone 10 mg 
(n=11)
3 27.2
p=ns
Surgical approach
intraoral (n=34) *   7 * 20.6
exclusively extraoral 
(n=29)
1 3.5
p=0.042
DSWH present (days postoperatively)
range 7–92
mean 28
median 28
*One patient with combination of intra-extraoral 
approaches is omitted because DSWH appeared 
in the upper eyelid. 
DSWH: Disturbance in surgical wound healing
34
results
in Figure 7. DSWH occurred significantly 
more often in patients who received GCs 
(24.2%) than in those who did not (3.2%) 
(p=0.016). No dose-dependent effect between 
the total dose of 10 mg and 30 mg of DXE 
could be shown. In the DXE group, DSWH 
was established on average 30 days after 
surgery, the corresponding delay in patients 
not receiving DXE being 27 days (p=ns). 
The association between intraoral approach 
and DSWH was also significant (p=0.042). 
Figure 8 shows a patient with DSWH at the 
intraoral surgical site. Associations between 
DSWH and gender, time span from accident 
to surgery, age, and duration of surgery were non-significant. 
5.4 Occurrence of pulp necrosis of teeth in the 
fractured area after operative treatment of mandibular 
fracture and influence of dexamethasone (Study IV)
Of the total of 41 patients with mandibular fractures in Study II, 24 fulfilled the inclusion 
criteria for Study IV. Descriptive statistics of these patients are shown in Table 9. None of the 
teeth in the fracture line had undergone endodontic treatment before the injury, none showed 
chronic infection, and none were fractured. 
Associations between PN and predictors are presented in Table 10. PN was diagnosed in 
six patients (25%) and in 18.2% of the total of 33 teeth in contact with the fracture line. PN 
was diagnosed on average 115 (range 26–364) days after surgery. Four patients had one tooth 
with PN, and two patients had two teeth with PN. 
PN occurred more frequently in patients who had received perioperative DXE (30.0%) 
than in those who did not (21.4%); however, the difference was not significant. In the DXE 
group, PN was established on average 168 days after surgery, the corresponding delay in 
patients not receiving DXE being 83 days (p=ns). Associations between PN and gender, age, 
smoking, and site of fracture were non-significant. 
Figure 8. Intraoral wound dehiscence with 
infection one week after surgery of zygomatic 
fracture. The patient received a total dose of 
30 mg of dexamethasone related to surgery.
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Table 9. Descriptive statistics of 24 patients with 
mandibular fractures in the tooth baring area 
(Study IV).
Age (years)
range 18.1–50.9
mean 29.2
Gender No. of 
patients
% of 
24
male 23 95.8
female 1 4.2
Dexamethasone
yes 10 41.7
no 14 58.3
Smoker
yes 17 70.8
Fracture site
body 2 8.3
symphysis/parasymphysis 10 41.7
symphysis/parasymphysis  
+ angulus
10 41.7
body + angulus 2 8.3
Follow-up Months
range 3–19
average 10
Table 10. Association between pulp necrosis and 
predictor variables in 24 patients with mandibular 
fractures in the tooth-bearing area (Study IV).
Pulp necrosis 
present  
No. of patients
% of n
Gender
male (n=23) 6 26.1
female (n=1) 0 0
p=ns
Dexamethasone
yes (n=10) 3 30.0
no (n=14) 3 21.4
p=ns
Smoker
yes (n=17) 4 23.5
no (n=7) 2 28.6
p=ns
Localization of pulp necrosis
body (n=4) 0 0
symphysis/
parasymphysis 
(n=20)
6 30.0
p=ns
Pulp necrosis present  
(days postoperatively)
range 26–364
mean 115
median 72
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6. DISCUSSION
6.1 Methodological considerations
The occurrence of DSWH and the association between DSWH and DXE were analyzed 
retrospectively in 208 patients with different types of facial fractures (Study I) and prospectively 
in 41 patients with mandibular fractures (Study II) and in 64 patients with ZC fractures 
(Study IV). The occurrence of PN and its association with DXE were investigated in 24 
patients with mandibular fractures. The patient numbers were deemed sufficient for meaningful 
statistical analysis. 
The drop-out rates in Studies II and III were 8.9% and 12.3%, respectively. A 20% drop-
out rate is generally accepted in follow-up of orthopedic trauma, and drop-out rates of 10% 
or less have been shown to be strongly reliable (Zelle, Bhandari et al. 2013).
6.2 Use of glucocorticoids in association with 
operative treatment of facial fractures
A survey of North American members of the American Society of Maxillofacial Surgeons 
evaluated the prevalence of use of GCs by surgeons performing craniomaxillofacial or esthetic 
surgery (Assimes, Lessard 1999). The results revealed that GC use was common; 46.7% of 
the respondents used short-term, high-dose GCs perioperatively. However, a great variety of 
preparations were used either alone or in combination, and the regimens were very heterogeneous. 
The most commonly reported GCs were DXE (60%) and methylprednisolone (56%), but 
also hydrocortisone (8%) and betamethasone (4%) were used. The total GC doses given, as 
equivalent to DXE, varied notably, and the total number of doses ranged from 1 to 22. Length 
of medication varied from 1 to 6 days. Also the present study revealed great variations in GC 
use (Study I). Three different preparations were used, the total number of doses varied from 
1 to 3, the total doses, as equivalent to DXE, varied from 3.8 to 30 mg, and the total length 
of medication varied from 1 to 24 hours. 
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Several reasons exist for the marked variations in GC use among surgeons, the foremost 
being the lack of evidence-based recommendations. The only previously published randomized 
trial focusing on the effects of GCs in association with surgery of facial fractures came to the 
conclusion that a total dose of 1000 mg of methylprednisolone (equivalent to 190 mg of DXE) 
given as 4 doses of 250 mg every 6 hours is beneficial in reducing postoperative swelling after 
orbital surgery (Dan, Thygesen et al. 2010, Markiewicz, Brady et al. 2008, Flood, McManners 
et al. 1999). The total dose is notably higher than the maximum dose of 30 mg used in the 
present study. We did not aim to clarify the benefits of GCs in association with surgery of 
facial fractures, and therefore, it remains unclear whether the total dose of 30 mg of DXE is 
sufficient in reducing pain and edema. Moreover, facial fracture patients constitute an extremely 
heterogeneous group of fractures in terms of severity and extent and duration of treatment, 
so likely no all-inclusive regimen exists. Further studies are needed to determine optimal GC 
regimens for different types of facial fractures. 
6.3 Occurrence of disturbance in surgical wound 
healing after treatment of facial fractures and 
influence of glucocorticoids
The findings of the present study revealed that GCs may indeed have an adverse effect on 
surgical wound healing. In patients with different types of facial fractures (Study I) and in 
those with mandibular fractures (Study II), the association between DXE and DSWH was not 
significant. However, an increasing trend towards DSWH in the DXE groups was observed, 
despite the fact that all patients received antibiotics perioperatively. In patients with ZC fractures, 
a significant association between DSWH and DXE emerged (Study III); perioperative DXE 
administration eight-folded the occurrence of DSWH. Therefore, perioperative DXE cannot 
be recommended in open reduction and fixation of ZC fractures. 
In addition to DXE, also intraoral surgical approach was associated significantly with 
DSWH in patients with ZC fractures. A similar phenomenon was observed in a recent 
study of 177 patients with ZC fractures (Forouzanfar, Salentijn et al. 2013); of 9 wound 
infections, 8 occurred intraorally at the zygomatico-alveolar crest. In the present study, intraoral 
approach was a significant predictor for DSWH also in patients with different types of facial 
fractures (Study I). Moreover, all patients with mandibular fractures in Study II had been 
operated on with an intraoral approach, and the overall DSWH rate in these patients was 
notable (31.7%). The oral area in general and other local factors in particular, such as poor 
oral hygiene and poor clinical dental status, offer advantageous circumstances for bacterial 
infections. The results indicate that DXE should be used with caution in association with 
intraoral surgery of facial fractures, particularly if other local factors that increase the risk 
for wound infection are present. 
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Mastropietro et al. (2013) were the first authors to publish an association between 
increased cumulative duration of GC exposure and infection after pediatric cardiac surgery. 
The authors reviewed the files of 76 children, all of whom had received intraoperative 
methylprednisolone. Forty-eight percent had additionally received postoperative hydrocortisone 
and 86% periextubation DXE. Twenty-six children (36%) had postoperative infections that 
were significantly associated with days of GC exposure. 
A similar trend was observed in the present study. DSWH was diagnosed in 6 of the 100 
patients in Study I who had received GCs perioperatively. All 6 patients had received the 
maximal number of GC doses used in the study population, i.e., three DXE doses over 16 
hours (Table 4). The biological half-life of DXE is 36–54 hours. Thus, repeated administration 
of DXE over the first days causes accumulation and prolongs the effects of the medication, 
thus increasing the risk for DSWH. With regard to surgical wound complications, a single 
dose of DXE is likely safer than multiple doses; however, further studies are required to assess 
this hypothesis, and also to clarify whether a single-dose regimen is sufficient to decrease the 
tissue reactions that cause postoperative discomfort. 
An important finding of this study was the notable delayed occurrence of DSWH after 
surgery, being on average 47 days after different types of facial fractures (Study I), 31 days 
after mandibular fractures (Study II), and 28 days after ZC fractures (Study III). Overall, the 
longest delay of DSWH after surgery was more than 90 days. Moreover, in all three studies 
the delay was even longer when GCs had been used. 
DXE may mask the signs of infection and inflammation, and therefore, clinical verification 
of local disturbances may occur with a lag. Short-term DXE decreases inflammatory mediator 
release effectively (Bronicki, Backer et al. 2000, Jansen, van Oeveren et al. 1991). It also 
lowers postoperative CRP levels, indicating a weakening of the immune response (Abdelmalak, 
Bonilla et al. 2013). Despite the low CRP levels, DXE does not reduce postoperative infective 
complications. In a randomized and controlled study of 381 patients having elective major 
non-cardiac surgery under general anesthesia, CRP levels were significantly lower in patients 
receiving perioperative DXE than in those who did not (Abdelmalak, Bonilla et al. 2013). 
However, the surgical site infections were even more frequent in patients receiving DXE (10.9% 
vs. 7.4%). In the present study, the delayed occurrence of DSWH in patients receiving DXE 
can be explained by the mask effect. 
6.4 Occurrence of pulp necrosis of teeth in 
the fractured area after operative treatment of 
mandibular fracture and influence of dexamethasone
PN was found in 25% of patients and in 18% of teeth lying in the fracture line, figures that 
are lower than those observed by Oikarinen et al. (1990). In their study, the PN rate of teeth 
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dIscussIon
in the fracture line was 38%. The higher rate can be explained by at least by three factors. 
First, the inclusion criteria were different. In the study by Oikarinen et al., angle fractures as 
well as teeth requiring endodontic treatment during surgery were included in the analysis. 
Second, the fractures were treated with intermaxillary fixation, a treatment method not used 
in the present study. Third, the follow-up time in Study IV was on average 10 months, in 
contrast to 43 months in the other study. Since PN can occur months or even years after the 
injury, we can assume that the occurrence of PN in our patients would have been higher had 
they been followed up for a longer period. 
As was the case with DSWH, also PN occurred more often in patients who had received 
DXE. Moreover, the delay of PN was clearly longer after perioperative DXE. The findings 
emphasize that those patients who have teeth in the mandibular fracture line, in particular 
those who additionally receive perioperative GCs, should be referred to the general dentist 
for regular, long-term follow-up so that endodontic treatment can be initiated immediately 
when needed. 
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7. CONCLUSIONS
Study I revealed that GCs are commonly used by oral and maxillofacial surgeons in association 
with operative treatment of facial fractures. However, the regimens used are highly variable, 
likely because of the heterogeneity of the patients, who have injuries of varying severity and 
who undergo treatments of various extents and durations. Moreover, no evidence-based 
recommendations exist on the perioperative use of GCs. 
Our subsequent studies showed that GCs may indeed cause complications at the surgical site. 
In patients operated on for ZC fractures (Study III), DSWH was significantly associated with 
perioperative use of DXE as well as with the intraoral surgical approach. In patients operated 
on for different types of facial fractures (Study I), DSWH was associated significantly with 
the intraoral surgical approach. In these patients, no significant association between DSWH 
and perioperative use of GC was found; however, DSWH occurred more frequently in the 
GC group. Also in patients undergoing intraoral surgery of mandibular fractures (Study II), 
DSWH occurred more frequently in the DXE group. The results show that perioperative 
DXE cannot be recommended in conjunction with surgery of ZC fractures. GCs should 
also be administered with caution in surgeries of other facial fractures, particularly when the 
intraoral approach is used. 
Among patients with different types of facial fractures (Study I), those 6 patients who 
had received perioperative GCs and who ended up with DSWH had been administered the 
maximal number of GC doses used in the study population, i.e., three 10-mg doses every eight 
hours over 16 hours. With regard to surgical wound complications, a single dose of DXE is 
likely safer than multiple doses. However, further studies are required to assess this hypothesis 
and also to clarify whether a single-dose regimen is sufficient to achieve the desired effects 
of the medication, i.e., a decrease in the tissue reactions that cause postoperative discomfort. 
In patients with different types of facial fractures (Study I), mandibular fractures (Study 
II), and ZC fractures (Study III), the delay of DSWH was notably longer in the DXE groups. 
Particularly PN (Study IV) was observed much later in the DXE group, on average 168 days 
after surgery. The findings emphasize that those patients who have teeth in the mandibular 
fracture line, in particular those who additionally receive perioperative GCs, should be referred 
to the general dentist for regular, long-term follow-up so that endodontic treatment can be 
initiated immediately when needed. 
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8. SUMMARY
1. The use of GC regimens in association with operative treatment of different types of facial 
fractures varied significantly. DSWH was observed in 3.9% of patients. It occurred more 
often in patients who received GCs than in those who did not (6.0% vs. 2.8%, p=ns).
2. DSWH was observed in one-third of mandibular fracture patients (31.7%). It occurred 
more often in patients who received GCs than in those who did not (35.0% vs. 28.6%, 
p=ns).
3. DSWH was observed in 14.1% of ZC fracture patients. It occurred significantly more 
frequently in patients receiving GCs than in those who did not (24.2% vs. 3.2%, p=0.016). 
4. PN was observed in one-quarter of mandibular fracture patients (25.0%). It occurred 
more often in patients receiving GCs than those who did not (30.0% vs. 21.4%, p=ns).
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